Nordea Bank Finland Plc issues Equity-Linked Notes – Europæiske Medicinalvirksomheder 2019


 

Nordea Bank Finland Plc (the ”Issuer”) issues a series (A769) of Equity-Linked Notes due 19 December 2019, Europæiske Medicinalvirksomheder 2019, denominated in Danish Kroner (“DKK”) with ISIN Code DK0030350426 and Common Code 115146394 (the "Notes").

The Notes are to be issued on 18 December 2014 and will be redeemed on 19 December 2019 in accordance with the terms and conditions for “Replacement Basket” structure. The return of the Notes depends on the performance of a basket of five (5) equity shares (the “Reference Assets”) where the return of the two (2) best performing Reference Assets will be replaced with a replacement factor of indicative 27.00 per cent (the “Replacement Factor”).

Full information on the Issuer and the offer of the Notes is only available on the basis of the combination of the Final Terms of the Notes dated 8 December 2014 and the Base Prospectus as so supplemented.

The offer period for the Notes will take place during the period from 9 December 2014, 9:00 CET until 12 December 2014, 16.00 CET. The Aggregate Nominal Amount of the Notes and the final Replacement Factor will be determined after the subscription period and will be announced in a Final Terms Confirmation Announcement through NASDAQ OMX Copenhagen A/S.

The Issuer reserves its rights to cancel the offer if the aggregate principal amount of Notes subscribed on or before the issue date is less than DKK 25,000,000, if the Replacement Factor cannot be set to at least 24.00 per cent, or if any event of an economic, financial or political nature occurs and which may jeopardise a successful offer, as determined by the Issuer. The Issuer may also replace any of the Reference Assets at any time on or prior to Issue Date by a comparable type of underlying Reference Asset.

The Notes will be issued and registered with VP Securities A/S on 18 December 2014 and be admitted to trading and official listing on NASDAQ OMX Copenhagen A/S with the first day of trading on the same day.

We refer to the published Final Terms of the Notes.

Questions regarding the Notes may be directed to Peter Kijne, Nordea Markets, telephone 33 33 53 39.


Attachments

Press release NBF Europæiske Medicinalvirksomheder 2019.pdf FT NBF Europæiske Medicinalvirksomheder 2019_exe 20141208.pdf